Latham & Watkins advised Harmony Biosciences, while Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in the offering. Harmony Biosciences Holdings, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Dorsey & Whitney advised Rezolute, while Paul Hastings advised Jefferies and Cantor as joint book-running managers in the offering. Rezolute, Inc. (Nasdaq: RZLT) completed its underwritten...
You must be a Standard 1 Year member to access this content.
Thompson Hine advised Vaxart, while Paul Hastings LLP advised Oppenheimer & Co. as the sole bookrunner in the offering. Vaxart, Inc. (Nasdaq: VXRT) announced an underwritten...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised ProKidney, while Paul Hastings advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in the transaction. ProKidney Corp. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Cooley advised INOVIO Pharmaceuticals, while Paul Hastings LLP advised Oppenheimer & Co. and Citizens JMP as joint book running managers in the offering. INOVIO executed an...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan Securities LLC as the exclusive placement agent in the transaction. Leap Therapeutics, Inc. (Nasdaq:LPTX) has entered into a securities purchase agreement with...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised BofA Securities as the sole placement agent in the transaction. Century entered into a securities purchase agreement with a select group of...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan and Leerink Partners as co-lead placement agents, and Stifel co-placement agent, in the transaction. Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has entered...
You must be a Standard 1 Year member to access this content.
Covington & Burling represented Humacyte, while Paul Hastings advised TD Cowen, Cantor and BTIG in the offering. Humacyte, Inc. executed an underwritten public offering of 13,400,000 shares...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners on the matter. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the...
You must be a Standard 1 Year member to access this content.
